情绪稳定剂 (拉莫特里金,和瓦尔酸) 通过抑制神经细胞中TRPM2通道,减少双极性疾病模型 (Ouabain) 诱导的氧化应激和亡
相关实验视频
Updated: Jan 17, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Esra Nur Kaplan1, İbrahim Eren1, Mustafa Nazıroğlu2,3,4
1Department of Psychiatry, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye.
情绪稳定剂,酸和拉莫特里金通过抑制TRPM2通道来保护双极性疾病 (BD) 神经毒性. 这些治疗方法减少了氧化应激,亡和流入,为BD提供了潜在的治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 双极性疾病 (BD) 与线粒体反应性氧物种 (mROS),亡和 (Ca2+) 流入有关.
- 通过mROS激活TRPM2通道有助于神经系统疾病中的神经元死亡,包括潜在的BD.
- 像lamotrigine (LMT), (Li) 和酸 (VPA) 这样的情绪稳定剂具有抗氧化特性,但它们通过BD中TRPM2抑制的神经保护机制尚不清楚.
研究的目的:
- 研究LMT,Li和VPA对SH-SY5Y神经细胞中ouabain (OUA) 诱导的氧化神经毒性的神经保护作用.
- 确定这些保护措施是否涉及TRPM2通道的调制.
主要方法:
- 用OUA,LMT,Li,VPA或它们的组合对待SH-SY5Y神经细胞.
- 评估了TRPM2通道活性,mROS产生,细胞质ROS,脂质过氧化,线粒体膜潜力,亡标记物 (caspase-3, -8, -9),Zn2+水平和细胞活力.
- 使用TRPM2抗剂来确认通道参与.
主要成果:
- 对OUA的暴露增加了TRPM2活性,mROS,ROS,脂质过氧化,亡,Zn2+和细胞死亡.
- LMT,Li和VPA治疗,以及TRPM2抗剂,显著降低了OUA诱导的TRPM2刺激和电流密度.
- 这些情绪稳定剂还减少了OUA诱导的氧化应激和亡标志物,同时增加了细胞活力和抗氧化防御 (谷,谷过氧化酶).
结论:
- LMT,Li和VPA有效调节OUA诱导的氧化应激,亡,Zn2+水平和谷氨通路.
- 这些情绪稳定剂抑制TRPM2介导的Ca2+过量流入,这表明它们在BD中的神经保护的关键机制.
- 这些发现突显了这些药物的潜力,用于治疗与高mROS,Ca2+和Zn2+相关的BD.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
相关概念视频
Mania and Antimanic Drugs: Overview
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: Glutamate Antagonists